Tempest Therapeutics Inc
TPST
NASDAQ
Biotechnology
$1.02
USD
-0.16 (-13.25%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $18.86M
Volume 428.0K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-43.10M
TTM
+3.8%
YoY
Operating Cash Flow
$-26.38M
TTM
+22.1%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 3.3 | 4.1 | 3.0 | 3.5 | 5.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 10.9 | 8.0 | 3.6 | 4.1 | 27.7 |
Operating Income | -10.9 | -8.0 | -3.6 | -4.1 | -27.7 |
EBITDA | -10.9 | -7.9 | -3.5 | -4.0 | -27.7 |
Other Income / Expense | 0.2 | 0.1 | 0.1 | 0.1 | 0.0 |
Total Other Income / Expense | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
Income Before Income Taxes | -10.9 | -7.9 | -3.5 | -4.0 | -27.7 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -10.9 | -7.9 | -3.5 | -4.0 | -27.7 |
Consolidated Net Income / Loss | -10.9 | -7.9 | -3.5 | -4.0 | -27.7 |
Net Income Attributable to Common Shareholders | -10.9 | -7.9 | -3.5 | -4.0 | -27.7 |
Basic EPS | -$3.16 | -$2.07 | -$0.79 | -$0.82 | -$2.53 |
Diluted EPS | -$3.16 | -$2.07 | -$0.79 | -$0.82 | -$2.53 |
Basic Shares Outstanding | 3.4M | 3.8M | 4.4M | 4.9M | 10.9M |
Diluted Shares Outstanding | 3.4M | 3.8M | 4.4M | 4.9M | 10.9M |